Literature DB >> 2785883

Development of antibodies to HIV-1 is associated with an increase in circulating CD3+CD4-CD8- lymphocytes.

J B Margolick1, V Carey, A Muñoz, B F Polk, J V Giorgi, K D Bauer, R Kaslow, C Rinaldo.   

Abstract

This study investigated whether seroconversion with respect to human immunodeficiency virus, type 1 (HIV-1) was associated with an increase in lymphocytes expressing the CD3+CD4-CD8- phenotype. Proportions and absolute numbers of CD3+, CD4+, and CD8+ lymphocytes were determined prospectively over a 2.5-year period on 4954 homosexual and/or bisexual men participating in the Multicenter AIDS Cohort Study. Of the 4808 men whose serostatus at entry could be verified, 1745 were seropositive (SP) for antibodies to HIV-1 at entry into study, 2795 were uniformly seronegative (SN) for HIV-1 for 30 months, and 268 were seroconverters (SC) with respect to HIV-1 during this period. For each of six semiannual evaluations, proportions and numbers of CD3+CD4-CD8- lymphocytes (calculated as CD3- (CD4 + CD8] were both significantly greater in the SP group than in the SN group (P less than 0.001). Mean CD3+CD4-CD8- levels in the SC group were indistinguishable from those in the SN group before seroconversion, but by 3-9 months after seroconversion the SC group demonstrated absolute numbers of CD3+CD4-CD8- lymphocytes which were significantly increased (P less than 0.001) compared to the SN group using linear regression methods with adjustment for correlation of measurements within an individual over time. An additional significant increase occurred by 21-27 months after seroconversion (P = 0.006). These results are consistent with an association of HIV-1 seroconversion with an increase in circulating T lymphocytes expressing the CD3+CD4-CD8- phenotype (double negative T cells), a decrease in CD3-CD4-CD8+ natural killer cells, or both. An increase in double negative T cells could reflect a host defense mechanism against HIV-1 or effects of HIV-1 on T cell development.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785883     DOI: 10.1016/0090-1229(89)90033-0

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

Review 1.  Lymphocyte subsets as surrogate markers in antiretroviral therapy.

Authors:  J R Bogner; F D Goebel
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 2.  Double-negative T cells during HIV/SIV infections: potential pinch hitters in the T-cell lineup.

Authors:  Vasudha Sundaravaradan; Kiran D Mir; Donald L Sodora
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

3.  Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice.

Authors:  Steven C Derrick; Idalia Yabe; Sheldon Morris; Siobhan Cowley
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

4.  Conversion of effector CD4+ T cells to a CD8+ MHC II-recognizing lineage.

Authors:  Elizabeth Robins; Ming Zheng; Qingshan Ni; Siqi Liu; Chen Liang; Baojun Zhang; Jian Guo; Yuan Zhuang; You-Wen He; Ping Zhu; Ying Wan; Qi-Jing Li
Journal:  Cell Mol Immunol       Date:  2020-02-17       Impact factor: 11.530

5.  Multifunctional double-negative T cells in sooty mangabeys mediate T-helper functions irrespective of SIV infection.

Authors:  Vasudha Sundaravaradan; Ramsey Saleem; Luca Micci; Melanie A Gasper; Alexandra M Ortiz; James Else; Guido Silvestri; Mirko Paiardini; John D Aitchison; Donald L Sodora
Journal:  PLoS Pathog       Date:  2013-06-27       Impact factor: 6.823

Review 6.  The functional role of CD8+ T helper type 2 cells.

Authors:  R A Seder; G G Le Gros
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

7.  Impact of the SCF signaling pathway on leukemia stem cell-mediated ATL initiation and progression in an HBZ transgenic mouse model.

Authors:  Wakako Kuribayashi; Kazuya Takizawa; Kenji Sugata; Madoka Kuramitsu; Haruka Momose; Eita Sasaki; Yuki Hiradate; Keiko Furuhata; Yoshihisa Asada; Atsushi Iwama; Masao Matsuoka; Takuo Mizukami; Isao Hamaguchi
Journal:  Oncotarget       Date:  2016-08-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.